NDATOPICALGELPriority Review
Approved
Jun 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
3/8 — Basic
Priority Review
TARGRETIN (bexarotene) by Bausch + Lomb. Approved for retinoid [epc]. First approved in 2000.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TARGRETIN (bexarotene) is a topical retinoid gel approved in 2000 for cutaneous T-cell lymphoma and other retinoid-responsive dermatologic conditions. It selectively binds retinoid X receptors (RXRs) to modulate gene expression and promote differentiation of malignant cells. The drug targets patients with mycosis fungoides and other rare skin lymphoproliferative disorders.
LOE Approaching
Product is approaching loss of exclusivity with modest competitive pressure (30/100), suggesting limited team expansion and focus on pipeline transition planning.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
Started Jun 2012
131 enrolled
Primary Cutaneous Anaplastic Large Cell LymphomaMycosis FungoidesCutaneous T-Cell Lymphoma
Phase I Study of CS-7017 and Bexarotene
Started Dec 2011
9 enrolled
Solid TumorsLymphomaMultiple Myeloma
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Started Mar 2010
34 enrolled
Cutaneous T-cell LymphomaMycosis FungoidesSezary Syndrome+1 more
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Started Jan 2010
59 enrolled
Refractory Cutaneous T-cell Lymphoma
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Started Nov 2006
37 enrolled
Lung Cancer
Worked on TARGRETIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.